Decreased Plasma Maresin 1 Concentration Is Associated with Diabetic Foot Ulcer

Table 1

Clinical and laboratory characteristics of the study participants.

	NC	T2DM	DFU
Sex (M/F)	43 (12/31)	40 (14/26)	13 (8/5)
Age (year)
BMI (kg/m^2)		^a	^b
Wc (cm)			^bd
WHR			^bd
SBP (mm hg)
DBP (mm hg)			85.38 + 9.35^bd
TC (mmol/L)
TG (mmol/L)		^b
HDL-c (mmol/L)			^a
LDL-c (mmol/L)
hsCRP (mg/L)
FPG (mmol/L)		^b	^bd
2hPG (mmol/L)		^b	^bd
HbA1C (%/mmol/mol)		^a	^bd
FINS (mU/L)			^a
AUC		^a	100.8251.02^b
AIR		^a	^b
HOMA-IR		^a	^bd
HOMA-β		^b	^b
Insulin treatment (/%)	0	0	8/61.54
OAD treatment (/%)	0	0	5/38.46

Data are presented as . NC: normal control; T2DM: newly diagnosed type 2 diabetes; DFU: diabetic foot ulcer; BMI: body mass index; Wc: waist circumference; WHR: waist hip ratio; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol; hsCRP: hypersensitive C reactive protein; FPG: fasting plasma glucose; 2hPG: 2 h postchallenge plasma glucose; FINS: fasting serum insulin; AUC: area under the curve of the first-phase (0-10 min) insulin secretion; AIR: acute insulin response; HOMA-IR: homeostasis model assessment for insulin resistance; HOMA-β: homeostasis model assessment for beta-cell function; OAD: oral antidiabetic drug. ^a compared with NC; ^b compared with NC; ^d compared with T2DM.